Efficacy and Safety of Cocktail of Ropivacaine for Local Infiltration Analgesia in Patients Undergoing Laparoscopic Cholecystectomy
NCT ID: NCT06819748
Last Updated: 2025-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
210 participants
INTERVENTIONAL
2025-02-14
2025-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Does the cocktail lower the The incidence of moderate to severe pain during movement stages within six hours after surgery.
Researchers will compare the cocktail to ropivacaine for incision local infiltration analgesia to see if the cocktail works to moderate the postoperative pain of ambulatory laparoscopic cholecystectomy patients.
Participants will:
Receive the cocktail or ropivacaine for incision local infiltration analgesia at the end of the surgery.
Answer the questions about postsurgical pain at rest or during motion(using a Numeric Rating Scale (NRS) of 0 to 10. Pain measurements were performed at 2, 6, 12, 24 hours,3,7,30 days and 3 months postoperatively.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Local Anesthetic Nebulization and Instillation for Pain Control After Laparoscopic Surgery
NCT01248819
Ropivacaine Use Intraincisionally Versus Intraperitoneally for Post-Laparoscopic Cholecystectomy Pain
NCT03265223
Local Infiltration With Ropivacaine Improves Postoperative Pain Control in Patients
NCT02649179
Dexmetomidine With Erector Spinae Plane Block in Cholecystectomy
NCT05369468
Local Anesthetic Nebulization for Pain Control After Laparoscopic Cholecystectomy
NCT01247857
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A group
Drug:cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10mg dexamethasone
The cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone
The patient receive the cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone as incision local anesthesia at the end of surgery
B group
Drug: 0.5%ropivacaine
0.5% ropivacaine
The patient receive 0.5% ropivacaine as incision local anesthesia at the end of surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone
The patient receive the cocktail of 0.5% ropivacaine ,5%sodium bicarbonate and 10 mg dexamethasone as incision local anesthesia at the end of surgery
0.5% ropivacaine
The patient receive 0.5% ropivacaine as incision local anesthesia at the end of surgery
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American society of Anesthesiologists physical status classification system I-II ④ 18 kg/㎡≤ BMI ≤ 30 kg/㎡ ⑤ No communication barriers, able to understand the research process and the use of pain scale.
* Signed informed consent
Exclusion Criteria
* History of chronic pain, long-term use of analgesic drugs (equivalent to ≥ 10mg oxycodone per day), alcohol abuse, gastrointestinal bleeding or perforation after application of non steroidal anti-inflammatory drugs
* Patients with ischemic heart disease, peripheral arterial vascular or cerebrovascular disease, or patients with pulmonary heart disease, active peptic ulcer or gastrointestinal bleeding, or patients with inflammatory bowel disease
* Patients taking monoamine oxidase inhibitors or within 2 weeks after discontinuation ⑤ Preoperative pain score (NRS ) was greater than or equal to 4 points ⑥ Participated in other clinical studies within three months
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sichuan Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xia Zhiying
resident physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dan Fan, M.D/PhD
Role: PRINCIPAL_INVESTIGATOR
Sichuan Provincial People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20247411
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.